We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

World's First Inhalable COVID-19 Vaccine Approved in China

By HospiMedica International staff writers
Posted on 06 Sep 2022

CanSino Biologics Inc. (Tianjin, China) has received approval from the National Medical Products Administration of China (NMPA) for Convidecia Air, its recombinant COVID-19 vaccine (Adenovirus Type 5 Vector) for inhalation to be used as a booster dose.

Utilizing the same adenovirus vector technological platform as the company's intramuscular version Convidecia, Convidecia Air provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. Convidecia Air is needle-free and can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath. Studies have indicated that Convidecia Air can induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus.


Image: The Convidecia Air inhalable COVID-19 vaccine has been approved for use as a booster dose (Photo courtesy of Pexels)
Image: The Convidecia Air inhalable COVID-19 vaccine has been approved for use as a booster dose (Photo courtesy of Pexels)

Related Links:
CanSino Biologics Inc. 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Surgical Camera
AIM 4K

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles

Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients